Subsequent oral or parenteral administration, barbiturates commonly cross the placental barrier and are distributed in the course of fetal tissues with maximum concentrations found in the placenta, fetal liver, and Mind; fetal blood stages approach maternal blood ranges adhering to parenteral administration
pentobarbital will decrease the extent or impact of doravirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will lower the extent or outcome of conivaptan by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
pentobarbital will minimize the level or impact of tamoxifen by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
pentobarbital will lessen the extent or influence of repaglinide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will lower the extent or effect of here triazolam by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
pentobarbital will lessen the extent or outcome of cevimeline by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unidentified.
pentobarbital will minimize the level or outcome of paclitaxel by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unidentified.
pentobarbital will minimize the extent or effect of carbamazepine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
pentobarbital will lessen the level or effect of bosentan by impacting hepatic enzyme CYP2C9/10 metabolism. Insignificant/Significance Unknown.
pentobarbital will minimize the level or result of bazedoxifene/conjugated estrogens by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
pentobarbital will lower the extent or effect of budesonide by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
pentobarbital will decrease the extent or effect of darunavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
After halting a CYP3A4 inducer, as the effects on the inducer decline, the fentanyl plasma focus will increase which could raise or extend each the therapeutic and adverse consequences.